Objective:Traditional Chinese medicine plays a significant role in the treatment of the pandemic of coronavirus disease 2019(COVID-19).Tanreqing Capsule(TRQC)was used in the treatment of COVID-19 patients in the Shang...Objective:Traditional Chinese medicine plays a significant role in the treatment of the pandemic of coronavirus disease 2019(COVID-19).Tanreqing Capsule(TRQC)was used in the treatment of COVID-19 patients in the Shanghai Public Health Clinical Center.This study aimed to investigate the clinical efficacy of TRQC in the treatment of COVID-19.Methods:A retrospective cohort study was conducted on 82 patients who had laboratory-confirmed mild and moderate COVID-19;patients were treated with TRQC in one designated hospital.The treatment and control groups consisted of 25 and 57 cases,respectively.The treatment group was given TRQC orally three times a day,three pills each time,in addition to conventional Western medicine treatments which were also administered to the control group.The clinical efficacy indicators,such as the negative conversion time of pharyngeal swab nucleic acid,the negative conversion time of fecal nucleic acid,the duration of negative conversion of pharyngeal-fecal nucleic acid,and the improvement in the level of immune indicators such as T-cell subsets(CD3,CD4 and CD45)were monitored.Results:COVID-19 patients in the treatment group,compared to the control group,had a shorter negative conversion time of fecal nucleic acid(4 vs.9 days,P=0.047)and a shorter interval of negative conversion of pharyngeal-fecal nucleic acid(0 vs.2 days,P=0.042).The level of CD3+T cells increased in the treatment group compared to the control group([317.09±274.39]vs.[175.02±239.95]counts/l L,P=0.030).No statistically significant differences were detected in the median improvement in levels of CD4+T cells(173 vs.107 counts/l L,P=0.208)and CD45+T cells(366 vs.141 counts/l L,P=0.117)between the treatment and control groups.Conclusion:Significant reductions in the negative conversion time of fecal nucleic acid and the duration of negative conversion of pharyngeal-fecal nucleic acid were identified in the treatment group as compared to the control group,illustrating the potential therapeutic benefits of using TRQC as a complement to conventional medicine in patients with mild and moderate COVID-19.The underlying mechanism may be related to the improved levels of the immune indicator CD3+T cells.展开更多
Objective: to explore the clinical value and effect of antiviral western medicine in patients with chronic hepatitis B. Methods: a retrospective study was conducted on 128 patients with chronic hepatitis B treated in ...Objective: to explore the clinical value and effect of antiviral western medicine in patients with chronic hepatitis B. Methods: a retrospective study was conducted on 128 patients with chronic hepatitis B treated in the infection department of our hospital from April 2020 to January 2021. 64 patients in the observation group were treated with antiviral western medicine and 64 patients in the control group were treated with liver protecting drugs. The effects of the two groups were compared. Results: the negative conversion rate of hepatitis B virus in the observation group was higher than that in the control group at 6, 12 and 24 weeks after treatment (P < 0.05);The negative conversion rate of hepatitis B surface antigen (HBsAg) was higher than that of the control group (P < 0.05). Conclusion: antiviral western medicine has a good effect in the treatment of chronic hepatitis B. It can effectively improve the negative conversion rate of HBsAg virus and hepatitis B virus, but it also has some limitations. Therefore, on the one hand, we should take the treatment of antiviral western medicine as the first choice for the clinical treatment of chronic hepatitis B, on the other hand, we should make a targeted analysis of the patient's condition to ensure that the treatment scheme is scientific and effective.展开更多
基金supported by Emergency Scientific Research Project of Shanghai Health Committee and Shanghai Administration of Traditional Chinese Medicine(No.2020YJ01)Shanghai Key Laboratory of Traditional Chinese Clinical Medicine(No.14DZ2273200)Shanghai Key Clinical Specialty(No.SHSLCZDZK05101)。
文摘Objective:Traditional Chinese medicine plays a significant role in the treatment of the pandemic of coronavirus disease 2019(COVID-19).Tanreqing Capsule(TRQC)was used in the treatment of COVID-19 patients in the Shanghai Public Health Clinical Center.This study aimed to investigate the clinical efficacy of TRQC in the treatment of COVID-19.Methods:A retrospective cohort study was conducted on 82 patients who had laboratory-confirmed mild and moderate COVID-19;patients were treated with TRQC in one designated hospital.The treatment and control groups consisted of 25 and 57 cases,respectively.The treatment group was given TRQC orally three times a day,three pills each time,in addition to conventional Western medicine treatments which were also administered to the control group.The clinical efficacy indicators,such as the negative conversion time of pharyngeal swab nucleic acid,the negative conversion time of fecal nucleic acid,the duration of negative conversion of pharyngeal-fecal nucleic acid,and the improvement in the level of immune indicators such as T-cell subsets(CD3,CD4 and CD45)were monitored.Results:COVID-19 patients in the treatment group,compared to the control group,had a shorter negative conversion time of fecal nucleic acid(4 vs.9 days,P=0.047)and a shorter interval of negative conversion of pharyngeal-fecal nucleic acid(0 vs.2 days,P=0.042).The level of CD3+T cells increased in the treatment group compared to the control group([317.09±274.39]vs.[175.02±239.95]counts/l L,P=0.030).No statistically significant differences were detected in the median improvement in levels of CD4+T cells(173 vs.107 counts/l L,P=0.208)and CD45+T cells(366 vs.141 counts/l L,P=0.117)between the treatment and control groups.Conclusion:Significant reductions in the negative conversion time of fecal nucleic acid and the duration of negative conversion of pharyngeal-fecal nucleic acid were identified in the treatment group as compared to the control group,illustrating the potential therapeutic benefits of using TRQC as a complement to conventional medicine in patients with mild and moderate COVID-19.The underlying mechanism may be related to the improved levels of the immune indicator CD3+T cells.
文摘Objective: to explore the clinical value and effect of antiviral western medicine in patients with chronic hepatitis B. Methods: a retrospective study was conducted on 128 patients with chronic hepatitis B treated in the infection department of our hospital from April 2020 to January 2021. 64 patients in the observation group were treated with antiviral western medicine and 64 patients in the control group were treated with liver protecting drugs. The effects of the two groups were compared. Results: the negative conversion rate of hepatitis B virus in the observation group was higher than that in the control group at 6, 12 and 24 weeks after treatment (P < 0.05);The negative conversion rate of hepatitis B surface antigen (HBsAg) was higher than that of the control group (P < 0.05). Conclusion: antiviral western medicine has a good effect in the treatment of chronic hepatitis B. It can effectively improve the negative conversion rate of HBsAg virus and hepatitis B virus, but it also has some limitations. Therefore, on the one hand, we should take the treatment of antiviral western medicine as the first choice for the clinical treatment of chronic hepatitis B, on the other hand, we should make a targeted analysis of the patient's condition to ensure that the treatment scheme is scientific and effective.
